Clinical Trial Search

Primary: Change From Baseline in Total Dysmenorrheal Score at Final Evaluation — -2.5; -2.1; -1.9; -1.0 scores on a scale — p=<0.001

Primary: Percentage of Subjects With Human Serum Bactericidal Assay (hSBA) Seroresponse — 80; 82; 87; 83 Percentage of participants

Primary: Number of Patients With at Least One Treatment Emergent Adverse Event (TEAE) — 9 Participants

Primary: Percent Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 3 — 9.53; 9.15 Percent Change

Primary: Pharmacokinetics Measured as Area Under Curve (AUC[0-12h]) — 35.5; 5.7 mg*hour/Liter

Primary: Number of Participants With Intracyclic Bleeding at Cycle 6 — 40; 4 participants

Primary: Proportion of Participants Able to Achieve Target (≥ 5*10^6 CD34+ Cells/kg) in 4 or Fewer Days of Apheresis — 0.593; 0.196; 0.407; 0.804 proportion of participants

Primary: "Drinking Days" in the Previous Month — 19.54; 15.18; 17.75; 22.11 Days — p=<0.001

Primary: Proportion of Participants Achieving a Target of ≥ 6*10^6 CD34+ Cells/kg in 2 or Fewer Days of Apheresis. — 0.716; 0.344; 0.284; 0.656 proportion of participants

Primary: Serum Levels of 25hydroxy Vitamin D(25(OH)D)Compared to the Due Control Group — 21.6; 21.2; 33.3; 31.5 nmol/L

Primary: Number of Participants With Reduction of at Least 1 Point at Week 4 Compared to Baseline in Ashworth Score in Wrist Flexors — 50; 28 Participants — p=<0.001

Primary: The Time (Days) From First Administration of Double-blind Treatment to the Development of Inadequate Analgesia at the Primary Osteoarthritis Pain Site. — 12.3; 17.2 days…

Primary: Actuations Registered by the Actuation Indicator — 167 Count

Primary: Overall Survival (OS) — 324; 241 days — p=0.00583

Primary: Lot to Lot Consistency of MenACWY as Measured by hSBA GMT Vaccine Group Ratios, Ages 11 to 18 Years — 29; 33; 31; 77 Titers